AstraZeneca will report its Q3 2026 earnings on October 30, facing pressure from generic competition on its cardiology drug Farxiga and a failed cardiology trial. However, strong oncology sales, led by Imfinzi and Enhertu, have driven overall revenue growth. The company expects mid-single-digit revenue growth for the quarter and has 25 key Phase III drug trial readouts coming in the next 18 months. Investors will watch if new drug launches can offset losses and support AstraZeneca's $80 billion revenue goal amid margin pressures and rising costs.
AstraZeneca's stock trades at USD 171.28 on Pluang as of Oct 26, 2026 19:01 WIB, down slightly by 0.12% for the day. This price sits closer to its 52-week low of USD 155.62 than its 52-week high of USD 209.48, highlighting some recent softness despite the company's ambitious drug pipeline and revenue goals. The dividend yield stands at 1.87%, offering some income potential amid margin pressures and rising costs.
A late-stage trial found that adding Amgen's Imdelltra to AstraZeneca's Imfinzi immunotherapy reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer, extending median survival to 21.1 months from 12.7 months with Imf...
Amgen announced Phase 3 DeLLphi-305 trial results where IMDELLTRA combined with AstraZeneca's IMFINZI reduced death risk by 58% and extended median overall survival to 21.1 months in extensive-stage small cell lung cancer patients. Nearly 80% of pati...
AstraZeneca remains a strong long-term Buy due to its robust product lineup and promising pipeline, aiming for $80 billion in revenues by 2030. The company currently has 14 blockbuster drugs and expects up to 12 more from its pipeline by decade's end...
